

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (BAP)
December 17 2020 @ 1:00 PM Eastern Standard Time***

Virtual Meeting

- **Administrative Meeting starts at 12:30 PM Eastern Standard Time**
- **Sign-In**
- **Roll Call**
- **Welcome and Opening Remarks**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the November 2020 meeting:

- **Drug Class Reviews**
 - *Attention Deficit Hyperactivity Disorder (ADHD): Stimulants Subclass*
 - *Respiratory Interleukins*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *azacitidine (Onureg) – Oral oncologic agent for acute myeloid leukemia (AML)*
 - *budesonide extended-release (Ortikos) – Gastrointestinal -1 GI Steroid for mild to moderate Crohn's Disease*
 - *budesonide/formoterol fumarate/glycopyrrolate inhalation aerosol (Breztri) – Triple combination Pulmonary-3 Agent for COPD*
 - *cysteamine 0.37% ophthalmic solution (Cystadrops) – Miscellaneous Ophthalmic for corneal cystine crystal deposits*
 - *decitabine/cedazuridine (Inqovi) – Oral combination oncologic agent for Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)*
 - *dexamethasone (Hemady) 20 mg tablets – Corticosteroids-Immune Modulator for multiple myeloma*

- *factor VIIa [recombinant]-jncw (Sevenfact) – Antihemophilic Factor for hemophilia A or B*
- *fluticasone oral inhaler (Armonair Digihaler) – Pulmonary-1 Agents: Inhaled Corticosteroids (ICS) for asthma*
- *fluticasone/salmeterol oral inhaler (AirDuo Digihaler) – Pulmonary-1 ICS-Long-Acting Beta Agonist (LABA) Combinations for asthma and COPD*
- *fostemsavir (Rukobia) – Oral antiretroviral for multi-drug resistant HIV-1 infection in heavily treatment-experienced adults*
- *insulin glargine (Semglee, Semglee Pen) – Basal Insulin*
- *levamlodipine (Conjupri) – dihydropyridine calcium channel blocker for hypertension*
- *metoclopramide nasal spray (Gimoti) – Gastrointestinal-2 Agent for diabetic gastroparesis*
- *monomethyl fumarate (Bafiertam) – Multiple Sclerosis*
- *nifurtimox (Lampit) – Miscellaneous Anti-infective agent for Chagas Disease in pediatrics*
- *octreotide (Mycapssa) – Miscellaneous Endocrine Agent for acromegaly*
- *ofatumumab injection (Kesimpta) – Multiple Sclerosis Agents*
- *opicapone (Ongentys) – Oral agent for “off episodes” associated with Parkinson’s Disease*
- *oxymetazoline ophthalmic solution (Upneeq) – Miscellaneous Ophthalmic agent for acquired blepharoptosis*
- *pralsetinib (Gavreto) – Oral oncologic agent for non-small cell lung cancer (NSCLC)*
- *risdiplam (Evrysdi) – Miscellaneous Neurologic Agent for spinal muscular atrophy (SMA)*
- *satralizumab-mwge injection (Enspryng) – Miscellaneous Neurological Agent for neuromyelitis optica spectrum disorder (NMOSD)*
- *triheptanoin (Dojolvi) oral liquid – Miscellaneous Metabolic Agents; oral liquid for long-chain fatty acid oxidation disorders in pediatrics and adults*

- *Sodium oxybate/calcium/magnesium/potassium oral solution (Xywav): Wakefulness Promoting Agent for narcolepsy*

➤ **Utilization Management Issues**

➤ ***Prior Authorization Criteria—New Manual PA Criteria***

- *Narcotic Analgesics – Tapentadol ER (Nucynta ER)*

➤ ***Prior Authorization Criteria—Updated PA***

- *Targeted Immunomodulatory Biologics (TIBs)*
 - *etanercept (Enbrel)*
 - *guselkumab (Tremfya)*
 - *tofacitinib (Xeljanz, Xeljanz oral solution)*
- *Hepatitis C Agents: Direct Acting Agents — sofosbuvir/velpatasvir tablets (Epclusa)*
- *Anticonvulsants-Antimania Agents — cannabidiol oral solution (Epidiolex)*
- *Hereditary Angioedema Agents — C1 Esterase Inhibitor [Human] (Haegarda)*

➤ **Brand Albuterol HFA (ProAir HFA) Copayment Change**

➤ **Section 702, National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2018: TRICARE Tier 4/Not Covered Drugs per 32 CFR 199.21(e)(3) Re-Review**

- *Diabetes Non-Insulin Drugs – Biguanides Subclass: metformin ER gastric retention 24 hours (Glumetza brand and generics)*
- *Pain Agents – Combinations Subclass: naproxen/esomeprazole (Vimovo brand and generic)*
- *Corticosteroids-Immune Modulators – High Potency Topical Corticosteroid for Plaque Psoriasis: halobetasol propionate 0.05%foam (Lexette brand and generic)*

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.